National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Thailand Science Park, Pathumthani 12120, Thailand
Auto-generated profile, based on publicly available information
Jarunee Vanichtanankul
National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Thailand Science Park, Pathumthani 12120, Thailand
A series of 5‐[(phenethylamino)methyl]pyrimidine‐2,4‐diamines were assessed in silico as potential inhibitors of Plasmodium falciparum dihydrofolate reductase (PfDHFR), synthesised and tested for inhibitory activity against PfDHFR in vitro. The compounds displayed promising inhibitory activity against both wild‐type (Ki 1.3–243 nM) and quadruple mutant (Ki 13–208 nM) PfDHFR in the biochemical enzyme assay, but were less potent in the whole‐cell P. falciparum assay (IC50(TM4/8.2) 0.4–28 μM; IC50(V1S) 3.7–54 μM). Further investigation into the pharmacokinetic properties of these compounds may guide the development of more potent analogues.
Human serum albumin (HSA) is a key biomarker for early detection of kidney disorders such as microalbuminuria. However, its structural complexity and susceptibility to degradation in urine challenge current diagnostic assays, particularly immunoturbidimetric methods that depend on epitope stability. In this study, we expressed and characterized full-length recombinant HSA (rHSA) and its proteolytic fragment F8 (residues 496–585) in both Escherichia coli and rice-based systems to explore their suitability for biosensor validation and diagnostic use. Comparative analysis via SDS-PAGE, LC–MS/MS, and dynamic light scattering revealed differences in solubility and aggregation profiles between expression systems, with rice-derived rHSA showing greater resistance to proteolytic degradation. The F8 fragment retained structural integrity and remained detectable in both native and protease-treated samples. Using a previously developed Cy5-labeled ssDNA aptamer-based fluorescence aptasensor, we evaluated binding to rHSA and F8 across a clinically relevant concentration range (0.37–1500 μg/mL). Sigmoidal fluorescence recovery curves with R2 > 0.99 were observed for all recombinant proteins. Notably, the aptasensor successfully detected both targets even under conditions mimicking nonfresh urine, highlighting its diagnostic robustness. These findings establish recombinant F8 as a stable, diagnostically relevant biomarker candidate and confirm the practical utility of aptamer-based platforms for albumin detection in diverse testing scenarios.